In summary PARP inhibitors represent an exciting new class of antineoplasic drugs and there may well have much wider clinical indications not just restricted to BRCA1/2 mutant tumours but to others where PARP inhibitor treatment enhance HR deficiency and mitotic alterations, driving the cell towards a status of genomic instability. The gene discussed is PARP1; the disease is neoplasm.